Pfizer

SARS-CoV-2 vaccine developers are evaluating further vaccine doses as well as modified doses to keep up with new viral variants, according to CNN.

Reuters reports that no serious safety concerns have been identified in the first month of SARS-CoV-2 vaccinations in the US.

Two studies indicated that the SARS-CoV-2 vaccines from Pfizer-BioNTech and Moderna have lower neutralizing antibody responses to the B.1.351 viral lineage, according to the Washington Post.

An initial analysis suggests the Pfizer-BioNTech vaccine could reduce viral load, the Guardian reports.

University of Oxford researchers are investigating whether combining different COVID-19 vaccines provides the same or better protection than one type of vaccine alone, Business Insider says.

The Associated Press reports a preliminary study suggests the Pfizer-BioNTech vaccine is effective against the new SARS-CoV-2 variant.

The European Medicines Agency has recommended the conditional approval of Pfizer and BioNTech's SARS-CoV-2 vaccine, according to the Associated Press. 

The Food and Drug Administration granted an Emergency Use Authorization for Pfizer and BioNTech's SARS-CoV-2 vaccine, the New York Times reports.

An advisory panel to the US Food and Drug Administration voted for authorizing Pfizer and BioNTech's SARS-CoV-2 vaccine, the Wall Street Journal reports.